Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN (SATURN): A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40mg or atorvastatin 80mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.

Trial Profile

Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN (SATURN): A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40mg or atorvastatin 80mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Rosuvastatin (Primary) ; Atorvastatin
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms SATURN
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Nov 2013 Results of an analysis of women versus men presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 17 Nov 2013 Results of an analysis of acute coronary syndrome (ACS) patients versus non-ACS patients presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top